ReviewActa gastroenterologica Latinoamericana
[Advances in the Treatment of Refractory Pediatric Constipation].
Review in Acta gastroenterologica Latinoamericana. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Refractory functional constipation is a persistent challenge inpediatrics. Beyond polyethylene glycol and traditional laxatives, newpharmacological and non-pharmacological therapies are emerging. Amongthe innovative medications, prosecretory agents like linaclotide(already approved for children over 6 years old), lubiprostone andplecanatide, wich increase intestinal secretion, stand out. Other drugs,such as prucalopride (5HT-4 agonist) and pyridostigmine, aim to improvemotility. Rectal and interventional therapies include transanalirrigation, -which has shown good results-; antegrade enemas andbotulinum toxin A injections, which are useful for specificdysfunctions. Biofeedback remains an effective tool. Neuromodulation isemerging as a promising option. Implanted sacral nerve stimulation andnon-invasive techniques such as percutaneous/transcutaneous tibial nervestimulation and transcutaneous sacral neuromodulation demonstrateimprovements in symptoms and quality of life. There are therapies thathave been little explored but show promise for the future, such asvibrating capsules, magnetic neurostimulation, and mind-body approacheslike hypnosis. Specific pediatric research and an individualizedtreatment approach are crucial to optimize adherence and outcomes inthese complex patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.